BLCO Stock Forecast & Price Target

Bausch & Lomb has demonstrated robust revenue growth across all three segments in the third quarter of 2025, with Vision Care achieving $736 million (8% YoY growth), Surgical at $215 million (4% YoY growth), and Pharmaceuticals at $330 million (8% YoY growth). The company has regained momentum in its premium intraocular lenses (IOLs) and has reported significant prescription growth for MIEBO, which demonstrates a 110% year-over-year increase, highlighting its unique market position within the dry eye treatment category. Furthermore, despite a net loss of $28 million in 3Q25, the loss was considerably less than anticipated, indicating improved operational performance and reinforcing the company's positive outlook for future growth.

Bausch & Lomb Corporation faces significant challenges in maintaining its leadership position in the competitive ophthalmology market, with a particularly promotional customer base that hampers pricing power. The company's limited product pipeline, resulting from insufficient investments during its time as a subsidiary of Bausch Health, necessitates additional business development efforts for accelerated growth. Furthermore, elevated levels of debt following the acquisition of Xiidra and macroeconomic uncertainties impacting elective procedures suggest that the company may struggle with long-term growth and profitability, negatively influencing investor sentiment.